Skip to Content

Danaher Corp DHR Stock Quote

| Rating as of


Morningstar‘s Stock Analysis DHR

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Danaher Turns In Strong Q3 but Highlights Upcoming COVID Headwinds; No FVE Change

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Danaher turned in stronger-than-anticipated operating results for the third quarter. However, COVID-19-related tailwinds may eventually turn into into headwinds, and the company's outlook for the rest of the year looks roughly in line with our expectations. So we do not anticipate changing our $215 fair value estimate based on this news, and the shares still appear moderately overvalued to us when considering Danaher's longer-term prospects.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DHR

Company Profile DHR

Business Description

In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.

2200 Pennsylvania Avenue, North West, Suite 800W
Washington, DC, 20037-1701
T +1 202 828-0850
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 80,000

Related News DHR